Global Rare Biomarkers Market – Industry Trends and Forecast to 2030

Get Exclusive Sample PDF of this Report Here

Rare Biomarkers Market Analysis and Size

A biological molecule or gene is referred to as a biomarker when it is utilized to precisely and effectively assess pharmacologic reactions, pathogenic processes, and biological processes. Biomarkers, which are often referred to as molecular markers or signature molecules, are present in tissue, various bodily fluids, and blood. They are frequently used to monitor the body's response to a specific treatment for a disease or condition. They help doctors diagnose patients' health and make wise therapeutic decisions. The use of biomarkers as stand-in endpoints during the development of treatments has been authorized by the U.S. Food and Drug Administration (FDA). The industry is being driven by a significant rise in the number of studies showing how circulating biomarkers are used to control the disease. The market's revenue growth has been significantly impacted by factors including rising demand for personalized medicine and rising desire for non-invasive disease treatment.

Data Bridge Market Research analyzes that the global rare biomarkers market which was USD 55.59 billion in 2022, would rocket up to USD 154.19 billion by 2030, and is expected to undergo a CAGR of 13.6% during the forecast period 2023 to 2030. This indicates the market value. “Circulating Cell Free DNA” dominates the product segment of the global rare biomarkers market owing to the increasing number of chronic diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Rare Biomarkers Market Scope and Segmentation

Get Exclusive Sample PDF of this Report Here

Market Definition

Biomarkers (also known as signature molecules or molecular markers) are utilized to check how the body responds to the treatment of any condition or disease and assist in examining organ functions and other health conditions. These play a vital role in imaging technology so that they can provide clear imaging of oncology tumors and other problems.     

Global Rare Biomarkers Market Dynamics

Drivers

• The increasing number of patients with a rising population

The rising need for non-invasive cancer diagnostics is one of the major factors propelling the rare biomarkers market forward. Furthermore, the rising number of cancer patients and research programs, as well as the rise in unhealthy lifestyles and chronic diseases such as diabetes and cardiovascular problems, all contribute to the market's overall growth.

•  The increasing number of CROs

The low cost of clinical trials in emerging countries, the increasing prevalence of cancer, and new research initiatives are expected to accelerate the rare biomarkers market's growth during the forecast period. The use of minimally invasive techniques for the identification of conditions such as cancer represents an opportunity that will start the development of the market in the forecast period.

• The growing importance of companion diagnostics

The global rare biomarkers market is expected to rise due to reasons such as rising cancer prevalence worldwide, increased finances and grants for biomarker research, and continual product improvements.   

Opportunity

• Increased government initiatives and R&D activities

Governments are also promoting biomarker technologies across Europe, which are boosting financing for biomarker research. As a result, increased R&D activities will likely boost the market forward in the coming years. Furthermore, the increasing use of biomarker technologies in drug development and genome mapping studies and a growing inclination for tailored medications are expected to provide opportunities for market growth.

Restraint/Challenge

• High investment requirements

Obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.

The global rare biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick tests, urine samples, and breath readings
• In February 2022, OncoDNA, a genomic and prognostic business, released the OncoDEEP kit. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customized cancer treatments for their patients

Global Rare Biomarkers Market Scope

The global rare biomarkers market is segmented into two notable segments based on product and end use. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Circulating Cell Free DNA (ccfDNA)
• Circulating Tumor Cells (CTCs)
• Exosomes/Extracellular Vesicles
• Product
• Isolation Kits and Reagents
• Blood Collection Tubes
• Systems
• Specimen Type
• Serum/Plasma
• Others
• Nucleic Acid and Other Biomolecules
• RNA
• DNA
• Others
• Application
• NIPT
• Oncology
• Transcriptomics
• Pharmacogenomics
• Transplant Rejection
• Population Screening
• Cardiovascular Diseases
• Circulating Cell Free RNA (ccfRNA) / miRNA
• Other Applications

End Use

• Research
• Research Labs/CROs
• Academic Institutes
• Diagnostics
• Laboratories
• Hospitals
• Prenatal Clinics

Global Rare Biomarkers Market Regional Analysis/Insights

The global rare biomarkers market is analyzed and market size insights and trends are provided by country, product, and end use as referenced above.

The countries covered in the global rare biomarkers market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America dominates the global rare biomarkers market due to the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of chronic conditions, and the rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global rare biomarkers market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global rare biomarkers market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the surgical microscopes market. The data is available for the historic period 2010-2020.

Competitive Landscape and Global Rare Biomarkers Market Share Analysis

The global rare biomarkers market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the global rare biomarkers market are:

• F. Hoffmann-La Roche Ltd. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• QIAGEN (Germany)
• PerkinElmer, Inc. (U.S.)
• Merck KGaA (Germany )
• Bio-Rad Laboratories, Inc. (U.S.)
• Enzo Biochem, Inc. (U.S.)
• Charles River Laboratories International, Inc. (U.S.)
• Eurofins Scientific (Luxembourg)
• Agilent Technologies, Inc. (U.S.)
• Bruker (U.S.)
• Siemens (U.S.)
• Epigenomics AG (Germany)
• General Electric (U.S.)

SKU-53716